Cancer Immunotherapy Market Is Expected to Reach $309.67 Billion by 2030, Grow at a CAGR Of 9.6% during Forecast Period 2023 To 2030 | Data By Contrive Datum Insights Pvt Ltd.

According to a market research study published by Contrive Datum Insights In the last few years, immunotherapy research and development have made a lot of progress. For example, immune checkpoint inhibitors, CAR-T cell therapy, and other new methods have been created. As these new treatments continue to be made and improved, they open up new ways to treat cancer and make patients' lives better.


Farmington, April 11, 2023 (GLOBE NEWSWIRE) -- The Global Cancer Immunotherapy Market Was Valued At $85.6 Billion In 2022 And Is Expected To Expand  $309.67 Billion By 2030 at a CAGR Of 9.6% From 2022 To 2030. The pharmaceutical business that makes and sells treatments that use the body's immune system to fight cancer is called the global cancer immunotherapy market. Immunotherapy is a type of treatment for cancer that uses the body's immune system. It can include immune checkpoint inhibitors, CAR-T cell therapy, cancer medicines, and other immune-based therapies. In the next few years, the global market for cancer immunotherapy is expected to grow by a large amount. This growth will be driven by things like the growing number of people with cancer, the growing desire for personalized medicine, and improvements in research and development of immunotherapy.

Request Sample Copy of Report Cancer Immunotherapy Market Size, Share & Trends Estimation Report By Type Outlook (Rigid, Semi-rigid & Flexible) By Material Type (Paper & Paper-based, Plastic, Metal, Glass & Others) By Application Outlook (Bakery & Confectionery, Dairy Products, Fruits &Vegetables, Meat, Poultry, & Seafood, Sauces & Dressings & Others) By Region, And Segment Forecasts, 2023 - 2030 ”, published by Contrive Datum Insights.

Segmentation Overview:

Product Outlook:

In the market for cancer treatment, monoclonal antibodies are the most popular type of product. These products work by focusing on specific proteins on the surface of cancer cells. This triggers the immune system to attack and kill these cells. Bristol-Myers Squibb, Merck, and Roche are all big names in this market area. Immune checkpoint inhibitors are a type of immunotherapy for cancer. They work by stopping certain proteins on cancer cells, which stops them from escaping the immune system. Bristol-Myers Squibb, Merck, and AstraZeneca are all big names in this market area.The goal of cancer vaccines is to get the immune system to spot cancer cells and attack them. You can use these vaccines to avoid cancer or to treat cancer that has already started. AstraZeneca and GlaxoSmithKline are two of the most important companies in this sector.

Application Outlook:

The biggest part of the cancer vaccine market is lung cancer. This is because lung cancer is common around the world and antibody treatments for this condition work well. Bristol-Myers Squibb, Merck, and AstraZeneca are all big names in this market area. Melanoma is a type of skin cancer that has been hard to treat with standard treatments in the past. But immunotherapy treatments have shown promise in this case, which has led to the creation of a number of new goods. Bristol-Myers Squibb, Merck, and Roche are all big names in this market area. In the market for cancer immunotherapy, colorectal cancer is the third biggest application segment. Immunotherapy treatments have shown promise in treating some kinds of colorectal cancer, especially those with high amounts of microsatellite instability. Bristol-Myers Squibb and Merck are two of the most important companies in this sector. Breast cancer is a common cancer in women, and immunotherapy drugs have shown promise in treating some kinds of advanced breast cancer. Roche and AstraZeneca are two of the most important companies in this category. Cancer immunotherapy can also be used to treat cancers of the head and neck, the bladder, and the prostate. These indications are smaller parts of the market, but they are likely to grow as new products come out in the coming years. Merck, Bristol-Myers Squibb, and AstraZeneca are all major players in these markets.

Regional Analysis:

North America is the biggest market for cancer immunotherapy. This is because there are a lot of people with cancer there, the healthcare system is well-developed, and there is a helpful regulatory environment. The United States is the biggest market in the area and accounts for the bulk of sales. Key players in the area include Bristol-Myers Squibb, Merck, and Roche.Europe is the second biggest market for cancer immunotherapy. This is because of things like the growing number of people with cancer, more people learning about immunotherapy treatments, and good regulatory policies. The United Kingdom, Germany, and France are the biggest markets in the area. Key players in the area include AstraZeneca, Bristol-Myers Squibb, and Merck. The Asia-Pacific area is the fastest-growing market for cancer immunotherapy. This is because there are a lot of patients there, the number of cancer cases is going up, and healthcare infrastructure is getting better. China is the biggest market in the region, followed by Japan and India. Key players in the area include Merck, Bristol-Myers Squibb, and AstraZeneca.

Buy this Premium Research Report@
https://www.contrivedatuminsights.com/buy/248613

Scope of Report:

Report AttributesDetails
Growth RateCAGR of 9.6% from 2023 to 2030.
Revenue Forecast by 2030 $309,667.65 million
By Product
  • Monoclonal Antibodies
  • Immunomodulators
  • Oncolytic Viral Therapies and Cancer Vaccines
By Application
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By End-use
  • Hospitals & Clinics
  • Cancer Research Centers
  • Others
By Companies
  • Pfizer Inc.
  • AstraZeneca
  • Merck & Co., Inc
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Genentech, Inc (Roche)
  • Novartis AG
  • Lilly
  • Johnson & Johnson Services, Inc
  • Immunocore, Ltd
Regions and Countries Covered
  • North America: (US, Canada, Mexico, Rest of North America)
  • Europe(Germany, France, Italy, Spain, UK, Nordic Countries, Benelux Union, Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, South Korea, Southeast Asia, Rest of Asia-Pacific)
  • The Middle East & Africa(Saudi Arabia, UAE, Egypt, South Africa, Rest of the Middle East & Africa)
  • Latin America(Brazil, Argentina, Rest of Latin America)
  • Rest Of the World
Base Year 2022
Historical Year 2017 to 2022
Forecast Year 2023 to 2030

Market Dynamics:

Restraining Factors:

There are a number of things that could stop the growth of the global market for cancer immunotherapy, such as:

Competition from other cancer treatments: There are many different ways to treat cancer, such as chemotherapy, radiation therapy, and focused therapy. These treatments can also help treat cancer, and their access may make the market for immunotherapy treatments smaller than it could be.

Lack of understanding of the immune system: Even though scientists have learned a lot about the immune system and how it can be used to treat cancer, there is still a lot they don't know. This lack of understanding could slow down the creation of new immune treatments that work well.

Opportunity Analysis:

The world market for cancer immunotherapy offers many chances for growth and new ideas, such as:

Personalized medicine: A big opportunity for the business is the development of personalized medicine methods that use genetic and other biomarkers to tailor treatments to each patient. Immunotherapy treatments have a lot of promise for personalized medicine, and making new tools and methods to help this could lead to a lot of growth.

Emerging markets: In developed markets like the US and Europe, the cancer immunotherapy market is already well-established, but there is a lot of room for growth in developing markets like China and India. Creating plans to grow into these markets could open up a lot of room for growth and new ideas in the business.

Key Segments Covered:

Top Market Players:

  • Pfizer Inc.
  • AstraZeneca
  • Merck & Co., Inc
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Genentech, Inc (Roche)
  • Novartis AG
  • Lilly
  • Johnson & Johnson Services, Inc
  • Immunocore, Ltd

By Product

  • Monoclonal Antibodies
  • Immunomodulators
  • Oncolytic Viral Therapies and Cancer Vaccines

By Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End-use

  • Hospitals & Clinics
  • Cancer Research Centers
  • Others

Regions and Countries Covered

  • North America: (US, Canada, Mexico, Rest of North America)
  • Europe: (Germany, France, Italy, Spain, UK, Nordic Countries, Benelux Union, Rest of Europe)
  • Asia-Pacific: (Japan, China, India, Australia, South Korea, Southeast Asia, Rest of Asia-Pacific)
  • The Middle East & Africa: (Saudi Arabia, UAE, Egypt, South Africa, Rest of the Middle East & Africa)
  • Latin America: (Brazil, Argentina, Rest of Latin America)
  • Rest Of the World

Check out more related studies published by Contrive Datum Insights:

  • Geospatial Analytics Market - At a compound annual growth rate (CAGR) of 12.8% between 2022 and 2030, the global geospatial analytics market is expected to expand from its 2022 level of USD 56.88 billion to a 2030 level of USD 63.61 billion.
  • Acne Treatment Market - In 2022, the global market for acne treatments was worth USD 4.7 billion, and it is projected to grow to USD 16.9 billion by 2030, with a compound annual growth rate (CAGR) of 4.2%.
  • Medical Devices Market- In 2021, the size of the global medical devices market was put at USD 488.98 billion. The market is expected to grow from USD 495.46 billion in 2022 to USD 718.92 billion in 2030, at a compound annual growth rate (CAGR) of 5.5%.

Customization of the Report: The report can be customized as per client needs or requirements.For any queries, you can contact us on anna@contrivedatuminsights.com or +1 215-297-4078. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.

About Us:
Contrive Datum Insights (CDI) is a global delivery partner of market intelligence and consulting services to officials at various sectors such as investment, information technology, telecommunication, consumer technology, and manufacturing markets. CDI assists investment communities, business executives, and IT professionals to undertake statistics-based accurate decisions on technology purchases and advance strong growth tactics to sustain market competitiveness. Comprising of a team size of more than 100 analysts and cumulative market experience of more than 200 years, Contrive Datum Insights guarantees the delivery of industry knowledge combined with global and country-level expertise.

Social: Facebook / LinkedIn / Twitter

Contact Us:
Anna B. | Head Of Sales
Contrive Datum Insights
Phone: +
91 9834816757 | +1 2152974078
Email: 
anna@contrivedatuminsights.com

Website:
https://www.contrivedatuminsights.com
Contrive Datum Insights Press Releases
Latest Contrive Datum Insights Latest Reports